General Doptelet and Doptelet Sprinkle information
Doptelet and Doptelet Sprinkle are indicated for pediatric patients 1 year and older with thrombocytopenia in persistent or chronic ITP who have had an insufficient response to a previous treatment. Doptelet Sprinkle is indicated for patients aged ≥1 and <6 years. Doptelet tablets are indicated for patients aged 6 and older. Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis.1
Doptelet and Doptelet Sprinkle are orally bioavailable, small molecule TPO receptor agonists that stimulate proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets.1
You may see platelet counts rise in as few as 8 days.1 To read more about the clinical trials and results for Doptelet and Doptelet Sprinkle, visit our efficacy page.
Patients should store Doptelet tablets and oral granules at room temperature, meaning between 68°F to 77°F (20°C to 25°C). Doptelet tablets should also be stored in the original package. Please remind patients to store Doptelet, Doptelet Sprinkle, and all medicines out of the reach of children.1
Warnings and precautions (risk of blood clots with TPO-RA class)1
Doptelet and Doptelet Sprinkle have been associated with thrombotic and thromboembolic complications in patients with persistent or chronic ITP.
Consider the potential increased thrombotic risk when administering Doptelet and Doptelet Sprinkle to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions and acquired risk factors.
Doptelet and Doptelet Sprinkle should not be administered to patients with persistent or chronic ITP in an attempt to normalize platelet counts. Monitor platelet counts and follow the dosing guidelines to achieve target platelet counts.
Monitor patients receiving Doptelet and Doptelet Sprinkle for signs and symptoms of thromboembolic events and institute treatment promptly.
In clinical trials, the most common adverse reactions, which occurred in 10% or more children living with low platelets in persistent or chronic ITP treated with Doptelet or Doptelet Sprinkle, were: viral infection,* nasopharyngitis, cough, pyrexia, oropharyngeal pain.1 To read more about adverse reactions, visit our safety page.
*Viral infection includes viral upper respiratory infection, viral infection, COVID-19, parainfluenza virus infection, and rhinovirus infection.1
Inpatient use of medications is enabled on an individual basis by institutions, but Doptelet and Doptelet Sprinkle are readily available for institutions to order for outpatient use through our Specialty Distributor network. See more info via our Access Guide.
There are no food-type restrictions with Doptelet or Doptelet Sprinkle. In tablet form, patients must take Doptelet with food. In oral granules form, patients must take Doptelet with any of these recommended soft foods or liquids: applesauce, strawberry jelly, yogurt (plain), milk (whole or skim), orange juice, pediatric electrolyte solution (unflavored), or water.1
General ITP information
Immune thrombocytopenia (ITP) is an immune disorder characterized by low platelet counts (<100×109/L). The mechanisms of ITP can involve both increased platelet destruction and impaired platelet production.3
Common symptoms of immune thrombocytopenia include bruising, petechiae, bleeding, and fatigue. This is not a complete list of symptoms.3
Doptelet and Doptelet Sprinkle dosing information
Doptelet comes in two forms for treating persistent or chronic pediatric ITP—a tablet for ages 6 and older, and oral granules for ages ≥1 and <6 years. Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis.1
Doptelet Sprinkle is currently not available but is coming soon. Sign up to be notified as soon as it’s available.
Depending on product, oral granules or tablet, patients are recommended to start on 10 mg or 20 mg, respectively. Dose adjustments are based on platelet count response. Assess platelet counts weekly until a stable platelet count ≥50×109/L has been achieved, and then obtain platelet counts weekly for at least 4 weeks following discontinuation of treatment.. Do not exceed a daily dose of 40 mg. Please note that 10 mg or 20 mg, depending on product, is the initial dose regimen for all patients except those taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4.1 Refer to the Titration Calculator or the full Prescribing Information for more details on titration.
It is recommended that patients take their dose of Doptelet or Doptelet Sprinkle as soon as they remember, but they should not take 2 doses at one time to make up for a missed dose. It is advised that patients take their next Doptelet or Doptelet Sprinkle dose at their usual scheduled time.1 Refer to the full Prescribing Information for more information on dosing.
Doptelet and Doptelet Sprinkle may affect the way other medications work, and other medications may affect the way Doptelet and Doptelet Sprinkle work. Dose adjustments are recommended for pediatric patients living with low platelets in persistent or chronic ITP taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.1 Refer to the full Prescribing Information to learn more.
Financial support information
Yes, Doptelet Connect provides information on financial assistance programs for eligible patients with financial needs. Visit the access page to learn more about access and reimbursement, or you can request support from a Field Reimbursement Manager.
ITP=immune thrombocytopenia; TPO=thrombopoietin; TPO-RA=thrombopoietin receptor agonist.
Want more information?
Join the email list to learn more about Doptelet and Doptelet Sprinkle.
Image
- DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
- Data on file. Clinical study report for AVA-PED-301. 2025: Sobi, Inc.
- NORD (National Organization for Rare Disorders) website: immune thrombocytopenia. Available at: https://rarediseases.org/rare-diseases/immune-thrombocytopenia/. Accessed May 12, 2021.